Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophage Activation Syndrome | 4 | 2022 | 101 | 1.120 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 239 | 0.750 |
Why?
|
| Antirheumatic Agents | 5 | 2019 | 1347 | 0.750 |
Why?
|
| Coronary Aneurysm | 1 | 2021 | 222 | 0.690 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2021 | 554 | 0.640 |
Why?
|
| Withholding Treatment | 1 | 2019 | 580 | 0.560 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 2189 | 0.550 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 612 | 0.440 |
Why?
|
| Rheumatology | 3 | 2022 | 549 | 0.400 |
Why?
|
| Sacroiliitis | 2 | 2019 | 9 | 0.380 |
Why?
|
| Glucocorticoids | 4 | 2019 | 2125 | 0.300 |
Why?
|
| Uveitis | 2 | 2019 | 405 | 0.270 |
Why?
|
| Methotrexate | 3 | 2019 | 1708 | 0.260 |
Why?
|
| Synovial Fluid | 2 | 2022 | 365 | 0.240 |
Why?
|
| Biological Products | 3 | 2019 | 825 | 0.230 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2020 | 299 | 0.220 |
Why?
|
| Occupational Therapy | 2 | 2019 | 133 | 0.210 |
Why?
|
| Arthritis | 2 | 2022 | 647 | 0.180 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 527 | 0.170 |
Why?
|
| Cell Polarity | 1 | 2021 | 654 | 0.170 |
Why?
|
| Adenosine Deaminase | 1 | 2019 | 245 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2021 | 460 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 2021 | 587 | 0.160 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2017 | 100 | 0.160 |
Why?
|
| Neutrophils | 2 | 2022 | 3867 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2020 | 540 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2022 | 3609 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 667 | 0.150 |
Why?
|
| Consensus | 3 | 2019 | 2713 | 0.140 |
Why?
|
| Isoantigens | 1 | 2017 | 579 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 1851 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1778 | 0.130 |
Why?
|
| Remission Induction | 1 | 2019 | 2399 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2020 | 742 | 0.120 |
Why?
|
| Child | 10 | 2022 | 73636 | 0.120 |
Why?
|
| Ophthalmology | 1 | 2019 | 487 | 0.120 |
Why?
|
| Chemokines | 1 | 2017 | 954 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 2244 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 1756 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 2340 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1805 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 3055 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 1588 | 0.090 |
Why?
|
| Child, Preschool | 5 | 2021 | 41081 | 0.080 |
Why?
|
| Adolescent | 8 | 2022 | 84718 | 0.080 |
Why?
|
| Cytokines | 2 | 2021 | 7189 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 2913 | 0.080 |
Why?
|
| Humans | 22 | 2022 | 708843 | 0.080 |
Why?
|
| Quality Improvement | 2 | 2021 | 3733 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 3690 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 4226 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3885 | 0.070 |
Why?
|
| Infant | 3 | 2021 | 34261 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 10362 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 13274 | 0.060 |
Why?
|
| Inflammation | 1 | 2022 | 10019 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3153 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3275 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2022 | 3510 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7487 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2019 | 127 | 0.050 |
Why?
|
| Male | 10 | 2022 | 349524 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 17218 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2022 | 7994 | 0.050 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3696 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2019 | 237 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 71483 | 0.040 |
Why?
|
| Female | 10 | 2022 | 375205 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2019 | 248 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 445 | 0.040 |
Why?
|
| Algorithms | 1 | 2019 | 13647 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2019 | 266 | 0.040 |
Why?
|
| Ferritins | 1 | 2019 | 570 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1908 | 0.040 |
Why?
|
| Dermatomyositis | 1 | 2019 | 263 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2021 | 1082 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2017 | 453 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2022 | 759 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 651 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2017 | 569 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2022 | 3245 | 0.030 |
Why?
|
| Counseling | 1 | 2021 | 1504 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2040 | 0.030 |
Why?
|
| Knee Joint | 1 | 2021 | 1544 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 1574 | 0.030 |
Why?
|
| Reference Values | 1 | 2019 | 5041 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1482 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2159 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3179 | 0.030 |
Why?
|
| Proteomics | 1 | 2022 | 3244 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4383 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 4254 | 0.020 |
Why?
|
| Massachusetts | 1 | 2021 | 8712 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2021 | 4099 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 2100 | 0.020 |
Why?
|
| Pain | 1 | 2021 | 4636 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 8720 | 0.020 |
Why?
|
| Young Adult | 2 | 2022 | 55940 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 16306 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14836 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2021 | 21194 | 0.020 |
Why?
|
| Mass Screening | 1 | 2019 | 5182 | 0.010 |
Why?
|
| Aging | 1 | 2022 | 8358 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15252 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 61932 | 0.010 |
Why?
|
| Risk Factors | 2 | 2019 | 69553 | 0.010 |
Why?
|
| Adult | 3 | 2020 | 211041 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 7089 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23284 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 80876 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 34151 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 170486 | 0.010 |
Why?
|
Concepts
(113)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(61)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_